Navigation Links
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Date:8/2/2009

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. The Company also announced that the U.S. Food and Drug Administration (FDA) has accepted its treatment protocol for velaglucerase alfa and that Shire has begun its rolling submission of the New Drug Application (NDA) for velaglucerase alfa allowed under the Fast Track process.

"We are very pleased with the progress of the velaglucerase alfa program from both a clinical and regulatory perspective," said Sylvie Gregoire, President of Shire Human Genetic Therapies. "This data are consistent with those previously reported from the Phase I/II and extension studies. We will continue to work diligently with the FDA and other regulatory agencies to make velaglucerase alfa available as soon as possible to help meet the needs of the Gaucher community."

Shire's velaglucerase alfa program is the largest and most comprehensive set of Phase III clinical trials conducted to date for Gaucher disease. Over 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies.

Velaglucerase alfa is made using Shire's proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and carries a human glycosylation pattern.

Phase III Study Overview and Results

The first trial in the Phase III program to be completed was a multicenter, randomized, double-blind, two dose study of velaglucerase alfa in patients with Type 1 Gaucher disease. The primary goal of this study was to evaluate the safe
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  TNI BioTech, Inc. (OTCQB: TNIB) ... on the development, marketing and distribution of opioid-related ... proxy materials with the Securities and Exchange Commission ... Shareholders to be held on Thursday, September 4, ... record date for determining those shareholders eligible to ...
(Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... di prodotti per la cura dei disturbi respiratori del ... ha avuto un,ingiunzione permanente in Germania contro il produttore ... proibisce la vendita di apparecchiature da indossare in testa, ... e le maschere 220. La sentenza della Corte Regionale ...
(Date:7/28/2014)... 28, 2014  ResMed (NYSE: RMD ), ... treatment of sleep-disordered breathing and other chronic respiratory conditions, ... against Taiwanese medical device manufacturer APEX Medical ... APEX WiZARD 210 and 220 masks.  The judgment was ... Munich , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... Acuo Technologies®, a market leading provider of ... for archiving, collaboration and migration services, announces another ... The company achieved 25% growth over the previous ... growth rate of 55% in revenue, while adding ...
... Today, Siemens (NYSE: SI ) announces ... Medical Informatics Officer (CMIO), of the Health Services (HS) Business ... Health Information Exchange (IHIE), Marc recently served as ... role at Siemens, Marc will be responsible for clinical informatics ...
Cached Medicine Technology:Acuo Technologies Announces Another Significant Growth Year in Revenue and Implementations to Further the Company's Market Leading Position 2Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:7/28/2014)... A revised version of a surgical procedure to treat ... more than 90 percent of the time in patients ... the MGH Division of Plastic and Reconstructive Surgery report ... the non-endoscopic procedure all of whom had headaches ... symptom relief a year later. The team,s paper ...
(Date:7/28/2014)... 28, 2014 Cape Regional Medical ... Exchange technology solution in an effort to ... support collaboration with their New Jersey health information ... center located in New Jersey, serves the local ... a variety of inpatient and outpatient services. With ...
(Date:7/28/2014)... July 28, 2014 (HealthDay News) -- Endurance runners are ... an undetected heart condition, according to a new study. ... participating in events in warm climates are actually 10 ... stroke. Yet, the less common sudden death of a ... problems, such as an irregular heartbeat, often gets a ...
(Date:7/28/2014)... 2014 The Oakwood Foundation celebrated a ... Songe and Associates, PC that will benefit each community ... come. , The HBWS group is among the ... $2.5 million in donations. Through their latest gift, they ... Oakwood Women’s Healthcare Classic for the next 6 years; ...
(Date:7/28/2014)... Stimulating one of two dopamine-producing regions in the brain ... either isoflurane or propofol. In the August issue ... (MGH) report that rats anesthetized with continuous doses of ... stand up in response to electrical stimulation delivered to ... other major dopamine-releasing area, the substantia nigra, did not ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... To Conduct Conference Call Today at 11am ET - SOMERSET, ... TSTF ), a national provider of healthcare and administrative ... quarter ended March 31, 2009. TeamStaff,s operating revenues for the ... compared to $16.1 million in the comparable quarter last year. ...
... Recurring Revenues Climb 84%; Free Cash Flow ... Med Technologies(R), Inc. ("Global Med" or the ... healthcare information technology company, today reported profitability ... growth for the first quarter ended March ...
... BioMarin,s Efforts to Expand Treatment Options for Patients with ... BMRN ) announced today that it has ... for Rare Disorders (NORD), an organization dedicated to improving ... was presented on May 14 at NORD,s annual "Partners ...
... help control anxiety, experts say, , , FRIDAY, May 15 (HealthDay ... isn,t something associated with heights, a job interview or getting ... of worry and tension that affects twice as many women ... eroding their quality of life. , But a new study ...
... study shows CMV raises risk of hypertension, hardening of arteries ... infection that most adults harbor could be a cause of ... cytomegalovirus (CMV) were more likely to develop not only high ... atherosclerosis, according to a report in the May 15 issue ...
... The following news tips are based on abstracts or posters ... Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 ... 8 a.m. to noon on Monday, June 1, 2009, Antiparasitic ... , Seth J. Orlow, M.D., Ph.D., the Samuel Weinberg ...
Cached Medicine News:Health News:TeamStaff Reports Second Quarter Results 2Health News:TeamStaff Reports Second Quarter Results 3Health News:TeamStaff Reports Second Quarter Results 4Health News:TeamStaff Reports Second Quarter Results 5Health News:TeamStaff Reports Second Quarter Results 6Health News:TeamStaff Reports Second Quarter Results 7Health News:TeamStaff Reports Second Quarter Results 8Health News:TeamStaff Reports Second Quarter Results 9Health News:TeamStaff Reports Second Quarter Results 10Health News:TeamStaff Reports Second Quarter Results 11Health News:TeamStaff Reports Second Quarter Results 12Health News:TeamStaff Reports Second Quarter Results 13Health News:TeamStaff Reports Second Quarter Results 14Health News:TeamStaff Reports Second Quarter Results 15Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 2Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 3Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 4Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 5Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 6Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 2Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 3Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 4Health News:Fear Response May Stem From Protein in Brain 2Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3Health News:NYU Langone Medical Center's tip sheet to the 45th Annual Meeting of ASCO 2Health News:NYU Langone Medical Center's tip sheet to the 45th Annual Meeting of ASCO 3Health News:NYU Langone Medical Center's tip sheet to the 45th Annual Meeting of ASCO 4
Transcranial vascular DWL doppler....
Transcranil vascular DWL doppler....
... is a powerful automated system capable of ... from 6 user-programmable test protocols to begin ... Any tests not included in the comprehensive ... handled using the Doppler, PVR and PPG ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
Medicine Products: